Cloudflare Inc vs 10X Genomics Inc — how do they compare? Cloudflare Inc trades at $344.36 (market cap $122.12B), while 10X Genomics Inc trades at $79 (market cap $10.07B). The key difference: Cloudflare Inc is far larger — about 12.1× 10X Genomics Inc's market cap, and Cloudflare Inc is trading nearer its 52-week high, 10X Genomics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cloudflare Inc for 61 Days and 10X Genomics Inc for 92 Days on average.
| NET | TXG | |
|---|---|---|
Market Cap | $122.12B | $10.07B |
Volume | 2,321,930 | 5,657,286 |
Sector | Technology | Health |
52-Week High | $359.60 | $97.74 |
52-Week Low | $160.16 | $11.48 |
Typical Hold Time | 61 Days | 92 Days |
Enterprise Value | $121.49B | $9.59B |
Signals from Pluang's Aura AI — not financial advice
Cloudflare (NET) trades at $342.82, down 3.44% on the day, as the stock consolidates near recent highs. The company continues to demonstrate strong revenue growth with 2025 revenue reaching $2.17 billion, though profitability remains elusive with a net income margin of -8.21%. Recent product launches including Cloudflare Basin and partnerships with Deutsche Telekom highlight ongoing innovation. Technical indicators show a bullish trend with the current price trading between support at $340 and resistance at $348.
While Cloudflare shows impressive revenue momentum and strong analyst support (71% buy ratings), investors face valuation concerns with elevated P/S ratio of 48x and persistent losses. The stock's outlook depends on continued enterprise adoption and path to profitability, with key risks including competitive pressure and high growth expectations priced in.
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
Read more on NET →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →